Back to Search Start Over

Magnetic natural lipid nanoparticles for oral treatment of colorectal cancer through potentiated antitumor immunity and microbiota metabolite regulation.

Authors :
Li B
Zu M
Jiang A
Cao Y
Wu J
Shahbazi MA
Shi X
Reis RL
Kundu SC
Xiao B
Source :
Biomaterials [Biomaterials] 2024 Jun; Vol. 307, pp. 122530. Date of Electronic Publication: 2024 Mar 11.
Publication Year :
2024

Abstract

The therapeutic efficacy of oral nanotherapeutics against colorectal cancer (CRC) is restricted by inadequate drug accumulation, immunosuppressive microenvironment, and intestinal microbiota imbalance. To overcome these challenges, we elaborately constructed 6-gingerol (Gin)-loaded magnetic mesoporous silicon nanoparticles and functionalized their surface with mulberry leaf-extracted lipids (MLLs) and Pluronic F127 (P <subscript>127</subscript> ). In vitro experiments revealed that P <subscript>127</subscript> functionalization and alternating magnetic fields (AMFs) promoted internalization of the obtained P <subscript>127</subscript> -MLL@Gins by colorectal tumor cells and induced their apoptosis/ferroptosis through Gin/ferrous ion-induced oxidative stress and magneto-thermal effect. After oral administration, P <subscript>127</subscript> -MLL@Gins safely passed to the colorectal lumen, infiltrated the mucus barrier, and penetrated into the deep tumors under the influence of AMFs. Subsequently, the P <subscript>127</subscript> -MLL@Gin (+ AMF) treatment activated antitumor immunity and suppressed tumor growth. We also found that this therapeutic modality significantly increased the abundance of beneficial bacteria (e.g., Bacillus and unclassified-c-Bacilli), reduced the proportions of harmful bacteria (e.g., Bacteroides and Alloprevotella), and increased lipid oxidation metabolites. Strikingly, checkpoint blockers synergistically improved the therapeutic outcomes of P <subscript>127</subscript> -MLL@Gins (+ AMF) against orthotopic and distant colorectal tumors and significantly prolonged mouse life spans. Overall, this oral therapeutic platform is a promising modality for synergistic treatment of CRC.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1878-5905
Volume :
307
Database :
MEDLINE
Journal :
Biomaterials
Publication Type :
Academic Journal
Accession number :
38493672
Full Text :
https://doi.org/10.1016/j.biomaterials.2024.122530